InvestorsHub Logo
Followers 10
Posts 2086
Boards Moderated 0
Alias Born 05/15/2015

Re: rafunrafun post# 110540

Friday, 07/21/2017 10:15:25 AM

Friday, July 21, 2017 10:15:25 AM

Post# of 423945
Totally understand. My point is that, if they found 20% more cardiovascular events occurring in the drug group as opposed to the placebo, they would stop it for safety concerns. If the opposite is happening, they would not have any safety concerns so they would not look at it. They are looking to see if anything appears to be occurring in the drug group that is a potential safety issue which is not occurring at the same rate in the placebo group. That is all they are looking for in a safety check, IMHO.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News